Table 1.
Characteristics of hemophilic subjects with cleared and chronic HCV infection
| HCV cleared, no. (%) | HCV chronic, no. (%) | P | |
|---|---|---|---|
| Ancestry | |||
| African | 16 (19.1) | 68 (80.9) | |
| Non-African | 176 (28.0) | 452 (72.0) | .08 |
| Sex | |||
| Male | 183 (27.3) | 488 (72.7) | |
| Female | 9 (22.0) | 32 (78.0) | .46 |
| Type of coagulation deficiency | |||
| Hemophilia A | 141 (28.5) | 353 (71.5) | |
| Hemophilia B | 40 (26.0) | 114 (74.0) | |
| Other | 11 (17.2) | 53 (82.8) | .15 |
| Severity of coagulation deficiency | |||
| Mild | 34 (20.5) | 132 (79.5) | |
| Moderate | 31 (25.2) | 92 (74.8) | |
| Severe | 127 (30.0) | 296 (70.0) | .06 |
| Type of factor treatment* | |||
| NHT only or first | 65 (30.2) | 150 (69.8) | |
| Both, cryo/plasma first | 78 (27.5) | 206 (72.5) | |
| Cryo/plasma only | 32 (24.6) | 98 (75.4) | .52 |
*
Non-heat-treated (NHT) factor concentrate; cryoprecipitate or fresh-frozen plasma (cryo/plasma) used first (before the other) or exclusively